Chi Sheng Pharma & Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Chi Sheng Pharma & Biotech has a total shareholder equity of NT$1.2B and total debt of NT$40.0M, which brings its debt-to-equity ratio to 3.3%. Its total assets and total liabilities are NT$1.7B and NT$485.8M respectively. Chi Sheng Pharma & Biotech's EBIT is NT$73.4M making its interest coverage ratio -4.6. It has cash and short-term investments of NT$320.0M.
Key information
3.3%
Debt to equity ratio
NT$40.00m
Debt
| Interest coverage ratio | -4.6x |
| Cash | NT$320.04m |
| Equity | NT$1.23b |
| Total liabilities | NT$485.78m |
| Total assets | NT$1.71b |
Recent financial health updates
No updates
Recent updates
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend
Apr 06
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Mar 10Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 01
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield
Jan 05Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)
Dec 10Financial Position Analysis
Short Term Liabilities: 4111's short term assets (NT$741.5M) exceed its short term liabilities (NT$383.9M).
Long Term Liabilities: 4111's short term assets (NT$741.5M) exceed its long term liabilities (NT$101.9M).
Debt to Equity History and Analysis
Debt Level: 4111 has more cash than its total debt.
Reducing Debt: 4111's debt to equity ratio has increased from 0% to 3.3% over the past 5 years.
Debt Coverage: 4111's debt is well covered by operating cash flow (436.3%).
Interest Coverage: 4111 earns more interest than it pays, so coverage of interest payments is not a concern.